Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer.

Tadashi WatabeKazuko Kaneda-NakashimaKazuhiro OoeYuwei LiuKenta KurimotoTakashi MuraiYuka ShidaharaKenji OkumaMasanori TakeuchiMasayuki NishideAtsushi ToyoshimaAtsushi ShinoharaYoshifumi Shirakami

Published in: Annals of nuclear medicine (2021)

In the extended single-dose toxicity study of [211At]NaAt, administration of high doses resulted in weight loss, transient bone marrow suppression, and pathological changes in the testis, which require consideration in the FIH clinical trial.

Keyphrases

clinical trial
bone marrow
weight loss
endothelial cells
mesenchymal stem cells
oxidative stress
bariatric surgery
open label
randomized controlled trial
phase ii
study protocol
cerebral ischemia
brain injury
phase iii
oxide nanoparticles
obese patients
high fat diet induced